
A California jury handed down what has been reported to be the first antitrust jury verdict involving the cannabis industry. As the cannabis industry continues to grow and evolve, cannabis-related antitrust disputes may well increase.
The case, Richmond Compassionate Care Collective v. Koziol, et al., Case No. MSC16-01426 (California Superior Court for the County of Contra Costa), involved a dispute between medical marijuana collectives in Richmond, California. Plaintiff Richmond Compassionate Care Collective (“RCCC”) alleged that the defendants, directors of the collective Richmond Patient’s Group (“RPG”), conspired to prevent plaintiff from opening a dispensary by blocking plaintiff’s access to the limited inventory of commercial properties where medical marijuana dispensaries were permitted to operate pursuant to a local ordinance.
Specifically, RCCC contended that the defendants conceived a plan whereby they presented phony leases, letters of intent to lease or purchase, and purchase agreements to landlords with available commercial properties in an effort to “tie [the landlords] up with paper” so as to prevent RCCC from securing a property before its pending permit expired. Defendants likewise went door-to-door to landlords in an attempt to convince landlords not to lease or rent their properties to RCCC, and also demanded non-compete clauses in their own commercial leases to contractually prevent landlords from leasing or renting their properties to RCCC.
RCCC’s lawsuit alleged that defendants’ scheme constituted an unlawful group boycott in violation of California’s Cartwright Act, causing RCCC to suffer millions of dollars in damages. The case went to trial in August 2021 against three owners and directors of RPG: William Koziol, Darrin Parle, and Alexis Parle. On September 23, 2021, the jury returned a verdict against William Koziol and Darrin Parle, awarding $5,000,000 in damages, which will be automatically trebled to $15,000,000. The remaining defendant, Alexis Parle, was found not liable.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas